359 related articles for article (PubMed ID: 26529931)
1. [Anti-RANKL antibody].
Omiya T; Tanaka S
Nihon Rinsho; 2015 Oct; 73(10):1690-5. PubMed ID: 26529931
[TBL] [Abstract][Full Text] [Related]
2. [Anti-RANKL monoclonal antibody Denosumab (AMG162)].
Sugimoto T
Clin Calcium; 2011 Jan; 21(1):46-51. PubMed ID: 21187593
[TBL] [Abstract][Full Text] [Related]
3. [Updates of denosumab, anti-RANKL antibody for osteoporosis].
Tokuyama N; Tanaka S
Clin Calcium; 2014 Jan; 24(1):85-91. PubMed ID: 24369284
[TBL] [Abstract][Full Text] [Related]
4. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
5. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
Tanaka S
Am J Nephrol; 2007; 27(5):466-78. PubMed ID: 17652963
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of bone metastasis by denosumab, the human monoclonal neutralizing antibody to RANKL].
Yoneda T
Nihon Rinsho; 2012 Dec; 70(12):2165-71. PubMed ID: 23259391
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic agents for disorders of bone and calcium metabolism--Denosumab, a fully human monoclocal antibody-targeting RANKL as a therapy for cancer-induced bone diseases].
Mera K; Ito K
Clin Calcium; 2007 Jan; 17(1):37-46. PubMed ID: 17211092
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
Bai YD; Yang FS; Xuan K; Bai YX; Wu BL
Med Hypotheses; 2008 Aug; 71(2):256-8. PubMed ID: 18445511
[TBL] [Abstract][Full Text] [Related]
9. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
Kostenuik PJ; Nguyen HQ; McCabe J; Warmington KS; Kurahara C; Sun N; Chen C; Li L; Cattley RC; Van G; Scully S; Elliott R; Grisanti M; Morony S; Tan HL; Asuncion F; Li X; Ominsky MS; Stolina M; Dwyer D; Dougall WC; Hawkins N; Boyle WJ; Simonet WS; Sullivan JK
J Bone Miner Res; 2009 Feb; 24(2):182-95. PubMed ID: 19016581
[TBL] [Abstract][Full Text] [Related]
10. Denosumab in postmenopausal women with low bone mineral density.
McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
[TBL] [Abstract][Full Text] [Related]
11. Anti-RANKL antibody was approved for the treatment of osteoporosis in Japan.
Yasuda H
Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(4):209-16. PubMed ID: 23994799
[TBL] [Abstract][Full Text] [Related]
12. RANK ligand inhibition with denosumab for the management of osteoporosis.
Lewiecki EM
Expert Opin Biol Ther; 2006 Oct; 6(10):1041-50. PubMed ID: 16989586
[TBL] [Abstract][Full Text] [Related]
13. Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe?
Tankó LB
Curr Opin Investig Drugs; 2007 Oct; 8(10):830-5. PubMed ID: 17907059
[TBL] [Abstract][Full Text] [Related]
14. Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis.
Chiu YG; Ritchlin CT
Expert Opin Biol Ther; 2017 Jan; 17(1):119-128. PubMed ID: 27871200
[TBL] [Abstract][Full Text] [Related]
15. An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases.
Maldonado-Gonzales E; Pietschmann P
Wien Med Wochenschr; 2010 Sep; 160(17-18):458-63. PubMed ID: 20714812
[TBL] [Abstract][Full Text] [Related]
16. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
Bayer CM; Beckmann MW; Fasching PA
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
[TBL] [Abstract][Full Text] [Related]
17. Denosumab: RANKL inhibition in the management of bone loss.
Hamdy NA
Drugs Today (Barc); 2008 Jan; 44(1):7-21. PubMed ID: 18301800
[TBL] [Abstract][Full Text] [Related]
18. [Control of bone resorption by RANKL-RANK system].
Harada S; Takahashi N
Clin Calcium; 2011 Aug; 21(8):1121-30. PubMed ID: 21814016
[TBL] [Abstract][Full Text] [Related]
19. [The mechanism of anti-RANKL antibody in the treatment of metabolic bone diseases including osteoporosis - possible applications of anti-RANKL antibody to the treatment of cancer patients].
Yasuda H
Nihon Yakurigaku Zasshi; 2019; 153(1):11-15. PubMed ID: 30643086
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system.
Tanaka Y; Ohira T
Curr Opin Pharmacol; 2018 Jun; 40():110-119. PubMed ID: 29702364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
